VFC's Stock House Stock Watch: AntriaBio Volume Boost Indicates Growing Interest

(EstateNewsWire.com, March 05, 2013 ) New York, NY -- AntriaBio, Inc. (ANTB) remains a stock to watch this week, as outlined in this week's 'Weekly Stock Watch,' due to a notable increase in trading volume over the past couple of the weeks and the advancement to human trials of a once-weekly basal insulin shot that has the potential to eventually replace the current standards of care, which includes once-or-twice daily shots.

This is an abbreviated report. A full examination of AntriaBio's pipeline potential and trading action is available by visiting VFC's Stock House at: http://VFCsStockHouse.com

Having fallen off the recent highs set at $2.50, investors may be taking advantage of the current pullback as volume has notiecably increased over the past week. On Monday, in fact, ANTB shares registered their second-highest trading day of the year and were not too far off from seeing the most shares traded in one day since the symbol began trading in mid-January. Investors taking note of potential 'volume precedes price' action may anticipate an eventual move higher based on the recent volume and interest paid to this stock.

Over the long term, AntriaBio has the potential to enter a multi-billion dollar industry with a next-generation product that could drastically increase the quality of life for diabetic patients needing daily basal insulin shots as a sustained treatment option. Aside from this week's 'Weekly Stock Watch' report linked above, below is our original write-up on AntriaBio.

ANTB trades in a highly volatile sector, so there are key points to consider, as outlined below, but this is an emerging story to monitor these days.

AntriaBio Potentially Positioned For Both Long And Short Term Gains

AntriaBio, Inc. (ANTB) is an emerging story in the developmental biopharmaceutical sector that may be worth keeping on the radar as volume has been picking up of late and the company's potential to alter the scope of the future insulin delivery market by creating a once-weekly injection of insulin to replace a once-or-twice daily version is starting to gain increased exposure from popular financial media outlets and from the investing community as a whole. Relatively new to the trading scene, AntriaBio became public through a reverse merger earlier this year after having first purchased the assets of PR Pharmaceuticals from bankruptcy court. PR Pharma had already invested tens of millions of dollars into the preclinical development of the above-mentioned once-weekly basal insulin shot, now known as AB101, but was unable to see its development through to fruition as the depths of the economic crisis dried up funding for many developmental biopharmas.

Now controlling the AB101 assets, AntriaBio has positioned itself, pending successful trials, to eventually enter the multi-billion dollar market of basal insulin delivery that is now dominated by Sanofi-Aventis' Lantus and Novo Nordisk's (NVO) Levenir, each of which requires patients to receive at least one shot daily. Those two products alone pull in over eight billion dollars annually, highlighting the potential of AB101 to to steal quick market share, should it reach the point of commercialization. Emphasizing that once-weekly advantage, it's understandable why AB101 would be attracting the increased attention that it is right now, as some investors may consider this a ground floor opportunity of a potential next-generation technology.

For additional insights, see full report.

Disclosure: Long ANTB.

Follow the developments of ANTB and other small cap stocks at VFCsStockHouse.com

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

About VFCsStockHouse.com: VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.

For full disclaimer visit: http://vfcsstockhouse.com

VFC's Stock House

VFC

240-786-2111

vfc@vfcsstockhouse.com

Source: EmailWire.Com